Industry Newsgene therapyrare diseasekrystal biotechreimbursement
Krystal Biotech Raises Price Target, Reports Revenues
|
4.8
Krystal Biotech reported fiscal Q4 and full-year 2025 results on Feb. 17, revealing VYJUVEK net product revenues of $107.1 million for Q4 and $389.1 million for the year. On Feb. 25 Guggenheim raised its price target to $284 and reiterated a Buy rating; the company said it has secured over 660 US reimbursement approvals, more than 90 prescriptions in Germany, France and Japan, and $955.9 million in cash.
Scoring Rationale
Solid official financial disclosures and analyst upgrade but limited relevance to core data science audience.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
